ArticleCPT: pharmacometrics & systems pharmacology2022
Artificial intelligence-guided precision treatment of chronic kidney disease-mineral bone disorder.
Article in CPT: pharmacometrics & systems pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.
- Applications of artificial intelligence in chronic kidney disease: a systematic review.Revista de saude publica · 2026Pooled it
- Transforming hemodialysis care: a tripartite collaboration model among medical staff, AI agents, and robots.Clinical and experimental nephrology · 2026Review
- A physiology-based mathematical model of the renin-angiotensin system, bone remodeling, and calcium homeostasis: Effects of estrogen and renin-angiotensin system inhibitors.PLoS computational biology · 2026Article
- Artificial intelligence in chronic kidney disease: Early detection, risk prediction, and personalized treatment strategies.World journal of nephrology · 2026Review
- Circulating and Urinary CCL20 in Human Kidney Disease.International journal of molecular sciences · 2025Article
- Precision Dosing in Presence of Multiobjective Therapies by Integrating Reinforcement Learning and PK-PD Models: Application to Givinostat Treatment of Polycythemia Vera.CPT: pharmacometrics & systems pharmacology · 2025Article
- Chronic Kidney Disease-Mineral and Bone Disorder Management in 4D: The Case for Dynamic Treatment Regime Methods to Optimize Care.Current osteoporosis reports · 2025Review
- Anemia in Elderly Patients: Contribution of Renal Aging and Chronic Kidney Disease.Geriatrics (Basel, Switzerland) · 2025Review
- Leveraging quantitative systems pharmacology and artificial intelligence to advance treatment of chronic kidney disease mineral bone disorder.American journal of physiology. Renal physiology · 2024Article
- Review
- Application of artificial intelligence to chronic kidney disease mineral bone disorder.Clinical kidney journal · 2024Review
- Artificial intelligence-guided precision treatment of chronic kidney disease-mineral bone disorder.CPT: pharmacometrics & systems pharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Chronic kidney disease (CKD)-mineral bone disorder (MBD) is a complex clinical syndrome that begins early during CKD and evolves into one of the deadliest complications of CKD through its effects on the cardiovascular and skeletal systems. Achievement of treatment goals to decrease the risk of accelerated cardiovascular events and fractures has been challenging. We hypothesized that application of quantitative systems pharmacology (QSP) modeling combined with artificial intelligence techniques could improve the management of CKD-MBD with the goal of improving outcomes for patients with CKD. We present the implementation of a reinforcement learning (RL) approach to achieve the prescribed goals for serum calcium, phosphorus, and parathyroid hormone through concurrent dosing of phosphate binders, vitamin D analogs, and calcimimetics by simulation in 80 subjects in Matlab. In silico simulation results demonstrate that the application of a QSP model coupled with RL more effectively and quickly achieves treatment goals even in the setting of inferior simulated subject compliance with medical therapy and identifies key decision variables for therapeutic recommendations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.